Development and characterization of a novel liposome-based formulation of SN-38.

@article{Zhang2004DevelopmentAC,
  title={Development and characterization of a novel liposome-based formulation of SN-38.},
  author={Jing A. Zhang and Tong Xuan and Manjeet Parmar and Lan Ma and Sydney Ugwu and Shahid Ali and Imran Ahmad},
  journal={International journal of pharmaceutics},
  year={2004},
  volume={270 1-2},
  pages={93-107}
}
SN-38, 7-ethyl-10-hydroxycamptothecin, is the active metabolite of Irinotecan (CPT-11), a topoisomerase I inhibitor commercially available as Camptosar. SN-38 is approximately 200-2000-fold more cytotoxic than CPT-11. Despite its promising anticancer potential, SN-38 thus far has not been used as an anticancer drug due to its poor solubility in any pharmaceutically acceptable solvents. In addition, SN-38 has low affinity to lipid membranes; it tends to precipitate in aqueous phase resulting in… CONTINUE READING
48 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…